Breaking barriers in leptomeningeal disease: A Society for Neuro-Oncology and The American Society of Clinical Oncology consensus review on clinical trial design and basic science integration.

IF 13.1 1区医学 Q1 CLINICAL NEUROLOGY

Neuro-oncology Pub Date : 2026-10-01 DOI:10.1093/neuonc/noag126

Yolanda Piña, Maxine Umeh Garcia, Adrienne Boire, Andrew Brenner, David Ross Camidge, Susan Chang, Peter A Forsyth, Melanie Hayden Gephart, David Olayinka Kamson, Priya Kumthekar, Eudocia Quant Lee, Emilie Le Rhun, Barbara O'Brien, Elena Pentsova, David Piccioni, Jan Remsik, Inna Smalley, Jeffrey Wefel, Michael Weller, Jessica Wilcox, Jonathan T Yang, Seema Nagpal, Isabella Claudia Glitza Oliva

{"title":"Breaking barriers in leptomeningeal disease: A Society for Neuro-Oncology and The American Society of Clinical Oncology consensus review on clinical trial design and basic science integration.","authors":"Yolanda Piña, Maxine Umeh Garcia, Adrienne Boire, Andrew Brenner, David Ross Camidge, Susan Chang, Peter A Forsyth, Melanie Hayden Gephart, David Olayinka Kamson, Priya Kumthekar, Eudocia Quant Lee, Emilie Le Rhun, Barbara O'Brien, Elena Pentsova, David Piccioni, Jan Remsik, Inna Smalley, Jeffrey Wefel, Michael Weller, Jessica Wilcox, Jonathan T Yang, Seema Nagpal, Isabella Claudia Glitza Oliva","doi":"10.1093/neuonc/noag126","DOIUrl":null,"url":null,"abstract":"<p><p>Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow-up assembly convened in 2024 with a goal of developing an SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2299-2312"},"PeriodicalIF":13.1000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noag126","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow-up assembly convened in 2024 with a goal of developing an SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.

查看原文本刊更多论文

打破薄脑膜疾病的障碍：临床试验设计和基础科学整合的SNO-ASCO共识综述。

轻脑膜病（LMD）是一种毁灭性的癌症并发症，其发病率正在上升。首届LMD智库会议于2023年在神经肿瘤学会（SNO）和美国临床肿瘤学会（ASCO）中枢神经系统（CNS）年会上举行，召集了一批致力于以多学科方式理解和治疗LMD的国际临床医生和科学家。虽然这次会议为SNO/ASCO对LMD临床管理的共识审查奠定了基础，但LMD患者经常被排除在试验之外被认为是一个明确而普遍的挑战。为了解决这一差距，2024年召开了一次后续会议，目标是就临床研究的最佳实践达成SNO/ASCO共识；这包括解决工业和基础科学家在临床试验中的作用，为改进临床试验设计提供指导，并加速LMD患者进入临床试验。学术-行业伙伴关系和多机构合作对于促进我们对LMD的理解，扩大治疗可及性，并最终提高患者的生存率和生活质量至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuro-oncology 医学-临床神经学

CiteScore

27.20

自引率

6.30%

发文量

1434

审稿时长

3-8 weeks

期刊介绍： Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.